Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: An economic model from five European countries

Journal of Viral Hepatitis

Volumn 23, Issue 3, 2016, Pages 217-226

  Younossi, Z ^a   Brown, A ^b   Buti, M ^c   Fagiuoli, S ^d   Mauss, S ^e   Rosenberg, W ^f   Serfaty, L ^g   Srivastava, A ^f   Smith, N ^h   Stepanova, M ⁱ   Beckerman, R ^h  

^a Inova Fairfax Medical Campus ^*  (United States)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^e Center for HIV and Hepatogastroenterology   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g HÔPITAL SAINT ANTOINE   (France)

^h CBPartners   (United States)

ⁱ Center for Outcomes Research in Liver Diseases   (United States)

Author keywords

absenteeism; all oral regimen; economic burden; hepatitis C treatment; presenteeism; societal impact

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ABSENTEEISM; ARTICLE; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); DISEASE ERADICATION; EUROPE; GENOTYPE; HEALTH ECONOMICS; HEPATITIS C VIRUS; HUMAN; INCOME; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRESENTEEISM; PRIORITY JOURNAL; PRODUCTIVITY; SENSITIVITY ANALYSIS; WORK PRODUCTIVITY; ADOLESCENT; ADULT; AGED; ECONOMIC MODEL; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; QUESTIONNAIRE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DISEASE ERADICATION; EFFICIENCY; EUROPE; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; SOFOSBUVIR; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84957440472     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12483     Document Type: Article

References (51)

1. European Centre for Disease Prevention and Control. Health Topics: Hepatitis C. Available at: http://www.ecdc.europa.eu/en/healthtopics/hepatitis-C/Pages/index.aspx (accessed 1 October 2014).
2. Europe WHOROf. Hepatitis: Data and Statistics. Available at: http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics (accessed 1 October 2014).
3. Sy T, Jamal MM,. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41-46.
4. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
5. Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U,. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34.
6. Messina JP, Humphreys I, Flaxman A, et al,. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.
7. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H,. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57.
8. Bruggmann P, Berg T, Ovrehus AL, et al,. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (Suppl 1): 5-33.
9. Alter MJ,. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S.
10. Razavi H, Waked I, Sarrazin C, et al,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl 1): 34-59.
11. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM,. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-1029.
12. Manne V, Sassi K, Allen R, Saab S,. Hepatitis C and work impairment: a review of current literature. J Clin Gastroenterol 2014; 48: 595-599.
13. Scalone L, Fagiuoli S, Ciampichini R, et al,. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol 2015; 2: e000025.
14. Vietri J, Prajapati G, El Khoury AC,. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol 2013; 13: 16.
15. daCosta DiBonaventura M, Yuan Y, Wagner JS, L'Italien GJ, Lescrauwaet B, Langley P,. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol 2012; 24: 869-877.
16. Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R,. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology 2015; 61: 1471-1478.
17. Perrillo R, Rothstein KD, Rubin R, et al,. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11: 157-165.
18. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
19. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
20. Kowdley KV, Gordon SC, Reddy KR, et al,. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888.
21. Younossi ZM, Stepanova M, Marcellin P, et al,. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the Ion-1, 2 and 3 clinical trials. Hepatology 2015; 61: 1798-1808.
22. Younossi ZMSM, Nader F, Jacobson IM, et al,. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59: 2161-2169.
23. Younossi ZM, Stepanova M, Zeuzem S, et al,. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61: 228-234.
24. Aggarwal J, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z, Goss TF,. Work productivity among treatment-naive patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. J Viral Hepat 2015; 22: 8-17.
25. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.
26. Kantar Health. Italy National Health and Wellness Survey 2010-2013.
27. Kantar Health. Spain National Health and Wellness Survey 2010-2013.
28. Kantar Health. UK National Health and Wellness Survey 2010-2013.
29. Kantar Health. France National Health and Wellness Survey 2010-2013.
30. Huppe D, Zehnter E, Mauss S, et al,. Epidemiology of chronic hepatitis C in Germany-an analysis of 10 326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46: 34-44.
31. Poethko-Muller C, Zimmermann R, Hamouda O, et al,. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 707-715.
32. Mohd HK, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
33. Hodgson TA,. Costs of illness in cost-effectiveness analysis. A review of the methodology. Pharmacoeconomics 1994; 6: 536-552.
34. Office for National Statistics. Annual Survey of Hours and Earnings, 2013 Provisional Results. Available at: http://www.ons.gov.uk/ons/dcp171778-335027.pdf; 2013. (accessed 1 October 2014).
35. I.Stat. Orario contrattuale annuo lordo, netto, ferie e altre ore di riduzione Available at: http://dati.istat.it/Index.aspx?DataSetCodeDCSC-RETRCONTR1O26Lang = (accessed 1 October 2014).
36. European Commission Eurostat. Earnings Statistics: Median Gross Hourly Earnings. Available at: http://ec.europa.eu/eurostat/statistics-explained/index.php/Earnings-statistics (accessed 1 October 2014).
37. Instituto Nacional de Estadistica. Salario por hora según tipo de jornada (euros) Available at: http://www.ine.es/ss/Satellite?Les-ES%26c=INESeccion-C%26cid=1259925408327%26p=1254735110672%26pagenameProductosYServicios%2FPYSLayout%26param31259924822888%20%22Salario%20por%20hora%20seg%C3%BAn%20tipo%20de%20jornada%20(euros)%22; 2011. (accessed 1 October 2014).
38. Institut national de la statistique et des etudes economiques. Salaires horaires nets par sexe et par categorie socioprofessionelle en 2012. Available at: http://www.insee.fr/fr/themes/tableau.asp?reg-id=0%26ref-idNATTEF04115; 2012. (accessed 1 October 2014).
39. European Foundation for the Improvement of Living and Working Conditions. Developments in collectively agreed working time 2013. Available at: http://eurofound.europa.eu/observatories/eurwork/comparative-information/developments-in-collectively-agreed-working-time-2013; 2014. (accessed 1 October 2014).
40. Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxi A,. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res 2014; 6: 303-310.
41. Patruni BNE,. Hepatitis C: A projection of the healthcare and economic burden in the UK. Available at: http://www.rand.org/content/dam/rand/pubs/technical-reports/TR1300/TR1307/RAND-TR1307.pdf.; 2014. (accessed 1 October 2014).
42. Omland LH, Osler M, Jepsen P, et al,. Socioeconomic status in HCV infected patients-risk and prognosis. Clin Epidemiol 2013; 5: 163-172.
43. DiBonaventura M, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W,. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011; 14: 253-261.
44. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J,. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014; 161: 170-180.
45. El Khoury AC, Vietri J, Prajapati G,. The burden of untreated hepatitis C virus infection: a US patients' perspective. Dig Dis Sci 2012; 57: 2995-3003.
46. National Institute of Statistics and Economic Studies. Population totale par sexe et âge au 1er janvier 2014, France métropolitaine. Available at: http://www.insee.fr/fr/ppp/bases-de-donnees/%e2%80%a6/pop-1janvier-fm.xls; 2014. (accessed 1 October 2014).
47. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2013 26-Jun-2014. Available at: http://www.ons.gov.uk/ons/taxonomy/index.html?nsclPopulation#tab-data-tables; 2014. (accessed 1 October 2014).
48. I.Stat. Indicatori demografici. Available at: http://dati.istat.it/Index.aspx?DataSetCodeD;DCIS-INDDEMOG1%26Lang = (accessed 1 October 2014).
49. Instituto Nacional de Estadistica. Cifras de poblaciõn a 1 de enero de 2013. Resultados definitivos. Available at: http://www.ine.es/jaxi/tabla.do?path/t20/p321/serie/def/l0/%26file=01001.px%26type=pcaxis%26L=0; 2013. (accessed 1 October 2014).
50. Destatis Statistisches Bundesamt. Population by age groups: Germany. Available at: https://www.destatis.de/EN/FactsFigures/SocietyState/Population/CurrentPopulation/Tables-/lrbev01.html; 2013. (accessed 1 October 2014).
51. Cornberg M, Razavi HA, Alberti A, et al,. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (Suppl 2): 30-60.